Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 9665 - 9672 of 12038 results
Baker Proposes State Budget Focused on Savings
March 6, 2015| Alert| Viewpoint
Application Drafting Dangers Highlighted by Pacing Technologies v. Garmin International
March 6, 2015| Blog| Viewpoint
CMS Call Letter: Medicare Advantage Contracting Considerations
March 6, 2015| Blog| Viewpoint
And the Beat Goes On: NY State Assembly to Vote on GMO Labeling Law
March 5, 2015| Blog| Viewpoint
Some Thoughts on Employee Appreciation Day, including a Potential Wage and Hour Pitfall
March 5, 2015| Blog| Viewpoint
MLW: New Parental Leave Act Offers More Than Gender Neutrality
March 5, 2015| Blog| Viewpoint
Cleantech Law Alert: Jordan Collins on Open Atlantic Coast Oil and Gas Drilling, Restricted Alaskan Waters
March 5, 2015| Blog| Viewpoint
SEC Enforcement Director Discusses Issues for Pharmaceutical and Medical Technology Companies
March 5, 2015| Blog| Viewpoint
News & Press Releases
San Francisco Business Times featured Mintz’s new office lease in San Francisco at 525 Market St. The firm will be increasing its footprint in downtown by 50% to 29,000 square feet on a whole single floor with the new space.
Mintz advised the underwriters in connection with a $230 million public offering by Cogent Biosciences, Inc. of 25,555,556 shares of common stock, which includes 3,333,333 shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock, offered at a public offering price of $9.00 per share. The aggregate gross proceeds to Cogent from this offering were approximately $230 million, including proceeds from the exercise in full by the underwriters of the option to purchase additional shares, before deducting underwriting discounts and commissions and other offering expenses.
Mintz advised the underwriters in connection with a $200 million public offering by Soleno Therapeutics, Inc. of 2,352,941 shares of its common stock at a price to the public of $85.00 per share. The gross proceeds to Soleno from the offering were approximately $200 million before deducting underwriting discounts and commissions and other offering expenses. In addition, Soleno granted the underwriters a 30-day option to purchase up to an additional 352,941 shares of its common stock at the public offering price.
Events
Mintz x The Engine: Supercharging Your IP Strategy with Trade Secrets
The Engine, 750 Main St. Cambridge, MA 02139
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|